← Back to Search

Placebo

RIST4721 for Palmoplantar Pustulosis

Phase 2
Waitlist Available
Research Sponsored by Aristea Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is effective and safe for treating palmoplantar pustulosis, a skin condition.

Eligible Conditions
  • Palmoplantar Pustulosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of Subjects Achieving a 50% Reduction in PPPASI Score
Secondary outcome measures
Absolute Change From Baseline in PPPASI
Absolute Change From Baseline in PPPGA

Side effects data

From 2019 Phase 2 trial • 35 Patients • NCT03988335
33%
Diarrhoea
20%
Urine odour abnormal
13%
Musculoskeletal stiffness
13%
Nausea
13%
Neutropenia
13%
Folliculitis
13%
Abnormal faeces
13%
Procedural pain
7%
Decreased appetite
7%
Bacterial test
7%
Post procedural cellulitis
7%
Cough
7%
Blood glucose increased
7%
Increased appetite
7%
Blood triglycerides increased
7%
Headache
7%
Abdominal pain
7%
Hepatic enzyme increased
7%
Anxiety
7%
Concussion
7%
Pain in extremity
7%
Osteoarthritis
7%
Fatigue
7%
Skin fissures
7%
Leukopenia
100%
80%
60%
40%
20%
0%
Study treatment Arm
RIST4721 300 mg
Placebo

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: RIST4721 400 mgExperimental Treatment1 Intervention
RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
Group II: RIST4721 200 mgExperimental Treatment2 Interventions
RIST4721 200 mg: 2 active (100 mg) tablets + 2 placebo tablets once daily for 12 weeks
Group III: PlaceboPlacebo Group1 Intervention
Placebo: 4 placebo tablets once daily for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
RIST4721
2019
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Aristea Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
98 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How can I become a part of this research project?

"This psoriasis study is looking for 156 participants who are between 18 and 74 years old."

Answered by AI

Are octogenarians welcome in this experiment?

"The guidelines for who can participate in this trial state that individuals must be between 18-74 years old. Out of the 184 similar clinical trials, 32 are only for children and 152 are meant for adults over 65."

Answered by AI

Are there any open slots left for people who want to participate in this research project?

"Yes, the trial is still looking for participants. According to the clinicaltrials.gov listing, the research team originally posted the study on January 5th, 2022 and updated it most recently on November 4th of the same year."

Answered by AI

Are there different sites where this trial is being conducted around the country?

"There are 25 clinical trial sites for this medical study, which include the Clinical Science Institute in Santa Monica, Pennsylvania; UPMC Department of Dermatology in Pittsburgh, Texas; and Dermatology Clinical Research Center of San Antonio in San Antonio, Alberta."

Answered by AI

How many people have been chosen to participate in this clinical trial?

"A total of 156 patients are required for this trial, all of which must meet the specific inclusion criteria. Patients can enrol at various locations, such as Clinical Science Institute in Santa Monica, Pennsylvania and UPMC Department of Dermatology in Pittsburgh, Texas."

Answered by AI

What is the official US government stance on RIST4721?

"There is some evidence that RIST4721 is safe for human use, but since this is only a Phase 2 trial, more research needs to be done to support its efficacy."

Answered by AI

Who else is applying?

What state do they live in?
Kentucky
Kansas
How old are they?
18 - 65
What site did they apply to?
DS Research
Lynderm Research Inc.
Centre De Recherche Dermatologique Du Quebec Metropolitan Inc.
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

Recent research and studies
clinicaltrials.govStudy
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
2022. "A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05194839.
~24 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top